Corrections at AMEX Healthcare Sector

PharmAthene, Inc. (AMEX:PIP)

About PharmAthene, Inc. PharmAthene, Inc. is a biodefense company engaged in the development and commercialization of medical countermeasures against biological and chemical weapons. It has five product candidates in various stages of development: SparVax, recombinant protective antigen (rPA) anthrax vaccine; Valortim, a human monoclonal antibody for the prevention and treatment of anthrax infection; Protexia, a recombinant enzyme (butyrylcholinesterase), which mimics a natural bioscavenger for the

prevention or treatment of nerve agent poisoning by organophosphate compounds, including nerve gases and pesticides; a third generation rPA anthrax vaccine, and RypVax, a recombinant dual antigen vaccine for pneumonic and bubonic plague (rYP).

Statistics Symbol

PIP

Beta

1.42

Current Price

$3.89

Market Capitalization:

159.13M

52 week range

$1.25 - $4.96

Shares Outstanding

40.91M

Avg Volume

1.91M

Float:

19.81M

Financials As per its financials ending on September 30, 2010 PharmAthene, Inc. (AMEX:PIP) produced total revenue $.6.24 million which is slightly greater than last quarter’s revenue which was $4.78 million.

Although net income is still negative but it produced better result compared to last quarter’s net income.

The company’s cash flow from operation stood at negative $8.15 million as contrasted to last quarter’s cash flow from operation which was placed at negative $6.59million.

According to current financials total assets of company accumulate up to $12.30 million and its total liabilities and equity stand at $33.02 million and negative $11.41 million respectively.

Neuralstem, Inc. (AMEX:CUR)

About Neuralstem, Inc. Neuralstem, Inc. is focused on developing and commercializing of treatments for central nervous system disease based on transplanting human neural stem cells and small molecule drugs. The Company has developed and maintain a portfolio of patents and patent applications that form the base of its research and development efforts in the areas of neural stem cell research, small molecule research, and related technologies. The Company has also developed and patented a series of small molecule compounds (l

Statistics Symbol

CUR

Beta

1.26

Current Price

$2.14

Market Capitalization:

99.45M

52 week range

$1.60 - $3.49

Shares Outstanding

46.47M

Avg Volume

183,899.00

Float:

42.76M

Financials Neuralstem, Inc. (AMEX:CUR) produced operating income of negative $6.44 million in current quarter which shows better result compared to previous quarter’s operating income which was $9.23 million.

The company’s cash flow from operation stood at negative $7.23lion as contrasted to last quarter’s cash flow from operation which was placed at negative $4.88 million According to present quarter’s ending financials as on September 30, 2010 company’s assets mount up to $12.54 million on equity and return on assets both are decreasing. Total liabilities and total equity stand at $3.99million and$8.62 respectively.

Opko Health Inc. (AMEX:OPK)

About Opko Health Inc. Opko Health Inc. is a specialty healthcare company. The Company is focused on the discovery, development and commercialization of pharmaceutical products, vaccines, diagnostic technologies, and imaging systems. Its business consists of the development of a range of pharmaceutical products and diagnostic tests, and the development, commercialization and sale of ophthalmic diagnostic and imaging systems, and instrumentation products, as well as the sale of pharmaceutical products, over-the-counter products and medical devices to government, private and institutional markets in Chile and Mexico. In October 2009, the Company acquired Pharma Genexx, a company engaged in the marketing, sale, and distribution of pharmaceutical products, over-the-counter products and medical devices for

government, private and institutional markets in Chile. In February 2010, it completed the acquisition of Pharmacos Exakta.

Statistics Symbol

OPK

Beta

1.33

Current Price

$3.77

Market Capitalization:

962.69M

52 week range

$1.60 - $3.99

Shares Outstanding

255.36M

Avg Volume

362,064.00

Float:

111.62M

Financials Opko Health Inc. (AMEX:OPK) generated current quarterly total revenue of $7.60 million that are slightly greater than last quarter closing that was $7.46 million.

The company’s cash flow from operation stood at negative $17.16 million contrasted to last quarter’s cash flow from operation which was placed at negative $11.27 million Total assets of company mount up to $67.83 million as of 30th September, 2010 that is .30% greater than last quarter ending quarter but it managed to maintain the Current ratio. The company’s total equity is also gradually increasing which depicts that company is going to have less funding liquidity problems and more funds available to invest in future profitable opportunities.

DISCLAIMER DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR IN ONE OF OUR NEWSLETTERS.

We are not registered as a securities broker-dealer or an investment advisor either within the U.S. Securities and Exchange Commission (the “SEC�) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

The information contained on our website or in any of our newsletters should be viewed as commercial advertisement and is not intended to be investment advice. Any information found on our website, or in any of our newsletters is not provided to any particular individual with a view toward their individual circumstances. The information contained on our website, and in any newsletter we distribute, is not an offer to buy or sell securities. We distribute opinions, comments, and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained on our website or in one of our newsletters about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.

Always research your own investments and consult with a registered investment adviser or licensed stock broker before investing.

This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide

investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. ChartPoppers.com is a wholly-owned subsidiary of Seo Freisin, Inc.. While Seo Freisin has not been compensated for the distribution of this particular email, any future email regarding a specific company will be the result of an advertising and promotional campaign for which Seo Freisin, Inc. receives compensation. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. Seo Freisin and its affiliates currently hold no shares in the profiled company.

Seo Freisin, Inc., and/or its affiliates will hold, buy, and sell securities in the companies profiled. When compensated in shares, all readers should be aware that it is our policy to liquidate all shares immediately. We reserve the right to buy or sell the shares of any the companies mentioned in any materials we produce at any time. This compensation constitues a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies.

Information contained in our report will contain “forward looking statements” as defined under section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance asto the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.

We have no first-hand knowledge of any profiled company’s operations and thereforecannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in this report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of

information we provide to any person or entity (including, but not limited to, lost profits, loss opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).